Multiple Myeloma
Multiple Myeloma
Advertisement
Dustin SamplesConferences | May 2, 2023
Patients who remained MRD-negative for ≥12 months had better duration of response and progression-free survival.
Read More
Dustin SamplesMultiple Myeloma | March 27, 2023
The HealthTree Foundation for Multiple Myeloma interviews Dr. Urvi Shah about IVIG.
Dustin SamplesMultiple Myeloma | March 27, 2023
Fluorescence in situ hybridization can detect genetic abnormalities that allow stratification of disease risk.
Dustin SamplesMultiple Myeloma | March 27, 2023
Only 2 patients experienced adverse events higher than grade 1 or 2, and response rates were high.
Dustin SamplesMultiple Myeloma | March 20, 2023
Toxicity- and disease-related adverse outcomes can affect the quality of life in this high-exposure population.
Dustin SamplesMultiple Myeloma | March 20, 2023
Non-Hispanic Black and Hispanic patients reported worse mental health and poorer sleep than their non-Hispanic White peers.
Dustin SamplesMultiple Myeloma | March 20, 2023
Half of all patients in a synthesized analysis developed infections, and a quarter developed grade III/IV infections.
Dustin SamplesMultiple Myeloma | March 13, 2023
Survey respondents described transportation, information, and scheduling barriers to treatment.
Dustin SamplesMultiple Myeloma | March 13, 2023
With many new targeted drugs available, nurses are under pressure to keep up with administration and toxicity profiles.
Dustin SamplesMultiple Myeloma | March 13, 2023
Nurses at the Huntsman Cancer Institute believe their algorithm successfully predicts PJP and decreases CD4 monitoring costs.
Dustin SamplesMultiple Myeloma | March 8, 2023
Myelosuppression, bone disease, and acute renal failure are discussed in this review, and treatment options are provided.
Dustin SamplesMultiple Myeloma | March 8, 2023
Discussing results from ASH, Cindy Chmielewski from The Patient Story spoke with Drs. Caitlin Costello and Sagar Lonial.
Dustin SamplesMultiple Myeloma | March 8, 2023
It may be possible to eliminate the monitoring period after subcutaneous daratumumab and increase chair availability.
Dustin SamplesMultiple Myeloma | February 28, 2023
The new bispecific antibody boasted an overall response rate of more than 60 percent and has received accelerated approval.
Dustin SamplesMultiple Myeloma | February 28, 2023
Recognizing and managing distress, fatigue, and sexual dysfunction in patients with MM can be difficult.
Dustin SamplesMultiple Myeloma | February 28, 2023
Nurses should assess patients for bone pain and mobility at each encounter and should consider implementing an activity plan.
Dustin SamplesHematology & Blood Cancer | January 6, 2023
Interprofessional team-based care is the standard for patients undergoing HSCT. But who belongs on the team?
Leah LawrenceMultiple Myeloma | December 7, 2022
Results of the CASTOR trial show promise for three-drug regimen, including reduction in risk of death.
Emily MenendezMultiple Myeloma | November 28, 2022
Janssen’s Tecvayli has received accelerated approval, while Pfizer’s elranatamab has been designated a breakthrough ...
Cecilia BrownMultiple Myeloma | August 18, 2022
Isatuximab plus carfilzomib and dexamethasone led to a higher MRD negativity rate and more complete responses in MM.
Advertisement
Advertisement
Advertisement